12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Capesaris: Phase II data

Pooled data from 164 men with androgen deprivation therapy (ADT)-naïve advanced prostate cancer in the open-label, U.S. Phase II G200705 and G200710 trials showed that once-daily oral Capesaris for 28 days led to castration, the primary endpoint defined as a testosterone concentration of <50 ng/dL by day 60, in 49% of patients in the 1,000 mg arm and 56% of patients in the 2,000 mg arm vs. 94% of patients receiving Lupron Depot leuprolide. In castrated patients, Capesaris reduced mean serum...

Read the full 391 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >